Xilio Therapeutics Advances Tumor-Activated IL-12 Therapy Into Phase 2, Secures $17.5M Milestone from Gilead

2025-09-09 11:00:51 ET

Xilio Therapeutics (NASDAQ: XLO ) has begun patient dosing in the Phase 2 portion of its ongoing trial evaluating efarindodekin alfa (XTX301) , a tumor-activated IL-12 designed to selectively activate in the tumor microenvironment. The study will assess XTX301 as a monotherapy in patients with advanced solid tumors, following encouraging Phase 1 data that demonstrated favorable safety, partial responses, and durable interferon- signaling.

Alongside the clinical milestone, Xilio has also unlocked a $17.5 million development payment under its exclusive license agreement with Gilead Sciences. The company expects to receive the payment in Q4 2025, extending its cash runway into Q1 2027 and strengthening its ability to advance XTX301 without near-term financing pressure.

Investor takeaway:

• Clinical progress: Transition into Phase 2 validates the potential of XTX301 as a next-generation IL-12 immunotherapy.
• Strengthened balance sheet: The $17.5M payment improves financial flexibility and extends operating runway.
• Strategic partnership: The Gilead collaboration reinforces external confidence in XTX301's therapeutic promise.

Bottom line: Xilio's dual milestones--progressing XTX301 into Phase 2 and securing non-dilutive funding--underscore the company's momentum in advancing novel, tumor-activated immunotherapies for difficult-to-treat cancers.

The post Xilio Therapeutics Advances Tumor-Activated IL-12 Therapy Into Phase 2, Secures $17.5M Milestone from Gilead appeared first on PRISM MarketView .

COMTEX_468656295/2927/2025-09-09T10:00:51